Figure 1
Kaplan-Meier estimates of progression-free survival based on investigator assessment of response. (A) PFS for 29 patients treated at the optimal dosing regimen of pralatrexate 15 mg/m2 weekly for 3 of 4 (3/4) weeks and (B) for 41 patients treated at praltrexate ≥ 15 mg/m2 weekly for 3/4 weeks.
